MCID: SZR006
MIFTS: 58

Seizure Disorder

Categories: Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Seizure Disorder

MalaCards integrated aliases for Seizure Disorder:

Name: Seizure Disorder 53 6 3
Seizures 29 6 42
Epilepsy 71
Seizure 29

Classifications:



External Ids:

UMLS 71 C0014544

Summaries for Seizure Disorder

NINDS : 53 The epilepsies are a spectrum of brain disorders ranging from severe, life-threatening and disabling, to ones that are much more benign. In epilepsy, the normal pattern of neuronal activity becomes disturbed, causing strange sensations, emotions, and behavior or sometimes convulsions, muscle spasms, and loss of consciousness. The epilepsies have many possible causes and there are several types of seizures. Anything that disturbs the normal pattern of neuron activity—from illness to brain damage to abnormal brain development—can lead to seizures. Epilepsy may develop because of an abnormality in brain wiring, an imbalance of nerve signaling chemicals called neurotransmitters, changes in important features of brain cells called channels, or some combination of these and other factors. Having a single seizure as the result of a high fever (called febrile seizure) or head injury does not necessarily mean that a person has epilepsy. Only when a person has had two or more seizures is he or she considered to have epilepsy. A measurement of electrical activity in the brain and brain scans such as magnetic resonance imaging or computed tomography are common diagnostic tests for epilepsy.

MalaCards based summary : Seizure Disorder, also known as seizures, is related to seizures, benign familial infantile, 3 and benign neonatal seizures, and has symptoms including seizures, tremor and back pain. An important gene associated with Seizure Disorder is DIAPH1 (Diaphanous Related Formin 1), and among its related pathways/superpathways are Neuroscience and L1CAM interactions. The drugs Ethosuximide and Nitrazepam have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and cortex, and related phenotypes are mortality/aging and nervous system

MedlinePlus : 42 Seizures are symptoms of a brain problem. They happen because of sudden, abnormal electrical activity in the brain. When people think of seizures, they often think of convulsions in which a person's body shakes rapidly and uncontrollably. Not all seizures cause convulsions. There are many types of seizures and some have mild symptoms. Seizures fall into two main groups. Focal seizures, also called partial seizures, happen in just one part of the brain. Generalized seizures are a result of abnormal activity on both sides of the brain. Most seizures last from 30 seconds to 2 minutes and do not cause lasting harm. However, it is a medical emergency if seizures last longer than 5 minutes or if a person has many seizures and does not wake up between them. Seizures can have many causes, including medicines, high fevers, head injuries and certain diseases. People who have recurring seizures due to a brain disorder have epilepsy. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Epilepsy is a broad term used for a brain disorder that causes seizures. There are many different types of epilepsy. There are also many different kinds of seizures.

Wikipedia : 74 Epilepsy is a group of neurological disorders characterized by recurrent epileptic seizures. Epileptic... more...

Related Diseases for Seizure Disorder

Diseases in the Seizure Disorder family:

Seizures, Benign Familial Infantile, 1 Seizures, Benign Familial Infantile, 2
Seizures, Benign Familial Infantile, 3 Seizures, Benign Familial Infantile, 4
Seizures, Benign Familial Infantile, 5 Scn1a-Related Seizure Disorders

Diseases related to Seizure Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2934)
# Related Disease Score Top Affiliating Genes
1 seizures, benign familial infantile, 3 34.3 SCN2A KCNQ2
2 benign neonatal seizures 33.7 SCN2A SCN1A PNPO KCNQ2 CDKL5
3 malignant migrating partial seizures of infancy 33.6 TBC1D24 SCN2A SCN1A
4 benign familial neonatal epilepsy 33.2 SCN2A SCN1A KCNQ2 CDKL5
5 benign familial infantile epilepsy 33.0 SCN2A SCN1A KCNQ2 CDKL5
6 epilepsy, nocturnal frontal lobe, 1 32.5 SCN1A KCNQ2
7 genetic epilepsy with febrile seizures plus 32.4 SCN2A SCN1A
8 episodic ataxia 31.9 SCN2A SCN1A KCNQ2
9 early onset absence epilepsy 31.8 SCN2A SCN1A KCNQ2
10 christianson syndrome 31.7 MECP2 CDKL5
11 lubs x-linked mental retardation syndrome 31.6 MECP2 CDKL5
12 epileptic encephalopathy, early infantile, 9 31.6 SCN2A SCN1A KCNQ2 CDKL5
13 valproate embryopathy 31.5 NLGN1 MECP2
14 early myoclonic encephalopathy 31.4 TBC1D24 SCN2A SCN1A KCNQ2 CDKL5
15 chromosome 1p36 deletion syndrome 31.0 TBC1D24 NAALADL2 MECP2
16 partial motor epilepsy 31.0 TBC1D24 SCN2A SCN1A KCNQ2
17 epileptic encephalopathy, early infantile, 1 30.7 TBC1D24 SCN1A KCNQ2
18 visual epilepsy 30.4 SCN2A SCN1A PNPO MECP2 KCNQ2 CDKL5
19 low-grade astrocytoma 30.4 SCN2A SCN1A
20 electroclinical syndrome 30.3 TBC1D24 SCN2A SCN1A MECP2 KCNQ2 CDKL5
21 encephalopathy 30.3 SCN1A PNPO MECP2 CDKL5
22 epileptic encephalopathy, early infantile, 6 30.2 TBC1D24 SCN2A SCN1A PNPO MECP2 KCNQ2
23 hypertelorism 30.1 WHCR SCN1A MECP2
24 landau-kleffner syndrome 29.9 SCN2A SCN1A KCNQ2 CDKL5
25 lennox-gastaut syndrome 29.8 SCN2A SCN1A MECP2 KCNQ2 CDKL5
26 generalized epilepsy with febrile seizures plus 29.8 SCN2A SCN1A KCNQ2 CDKL5
27 epilepsy with generalized tonic-clonic seizures 29.7 SCN2A SCN1A
28 autosomal dominant nocturnal frontal lobe epilepsy 29.6 SCN2A SCN1A PNPO KCNQ2
29 epilepsy, myoclonic juvenile 29.5 SCN2A SCN1A PNPO KCNQ2 CILK1 CDKL5
30 epilepsy, idiopathic generalized 29.3 SCN2A SCN1A PNPO KCNQ2 CDKL5
31 childhood absence epilepsy 29.2 SCN2A SCN1A KCNQ2 CELF4 CDKL5
32 focal epilepsy 29.0 TBC1D24 SCN2A SCN1A MECP2 KCNQ2 CDKL5
33 west syndrome 28.9 TBC1D24 SCN2A SCN1A PNPO MECP2 KCNQ2
34 epilepsy 28.8 TBC1D24 SCN2A SCN1A PNPO MECP2 KCNQ2
35 benign epilepsy with centrotemporal spikes 28.7 TBC1D24 SCN2A SCN1A KCNQ2 CELF4 CDKL5
36 pervasive developmental disorder 28.5 SCN2A SCN1A NLGN1 MECP2 CELF4 CDKL5
37 microcephaly 28.1 VPS11 TBC1D24 SCN1A NLGN1 MECP2 DIAPH1
38 early infantile epileptic encephalopathy 28.0 TBC1D24 SCN2A SCN1A PNPO MECP2 KCNQ2
39 autism 28.0 SEZ6L2 SCN2A SCN1A NLGN1 MTR MECP2
40 multiple congenital anomalies-hypotonia-seizures syndrome 2 12.5
41 seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance 12.5
42 multiple congenital anomalies-hypotonia-seizures syndrome 1 12.4
43 multiple congenital anomalies-hypotonia-seizures syndrome 3 12.4
44 microcephaly, seizures, and developmental delay 12.4
45 microcephaly, short stature, and polymicrogyria with or without seizures 12.4
46 febrile seizures, familial, 4 12.4
47 seizures, benign familial infantile, 2 12.4
48 seizures, benign familial neonatal, 1 12.4
49 seizures, scoliosis, and macrocephaly/microcephaly syndrome 12.4
50 microcephaly, progressive, with seizures and cerebral and cerebellar atrophy 12.4

Comorbidity relations with Seizure Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Seizure Disorder:



Diseases related to Seizure Disorder

Symptoms & Phenotypes for Seizure Disorder

UMLS symptoms related to Seizure Disorder:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, non-epileptic convulsion

MGI Mouse Phenotypes related to Seizure Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.77 AP3D1 CELF4 CILK1 DIAPH1 HMGCR KCNQ2
2 nervous system MP:0003631 9.4 AP3D1 CDKL5 CELF4 CILK1 DIAPH1 KCNQ2

Drugs & Therapeutics for Seizure Disorder

Drugs for Seizure Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 828)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethosuximide Approved Phase 4 77-67-8 3291
2
Nitrazepam Approved Phase 4 146-22-5 4506
3
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
4
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
5
Lumefantrine Approved Phase 4 82186-77-4 6437380
6
Artemether Approved Phase 4 71963-77-4 119380 68911
7
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
8
Verapamil Approved Phase 4 52-53-9 2520
9
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
10
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
11
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
12
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
13
Morphine Approved, Investigational Phase 4 57-27-2 5288826
14
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
15
Methohexital Approved Phase 4 151-83-7 9034
16
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
17
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
18
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
19
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
20
Nicotine Approved Phase 4 54-11-5 942 89594
21
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
22
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
23
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
24
Labetalol Approved Phase 4 36894-69-6 3869
25
Ziprasidone Approved Phase 4 146939-27-7 60854
26
Cosyntropin Approved Phase 4 16960-16-0 16129617
27
Sodium citrate Approved, Investigational Phase 4 68-04-2
28
Vidarabine Approved, Investigational Phase 4 24356-66-9 32326 21704
29
Levodopa Approved Phase 4 59-92-7 6047
30
Cycloserine Approved Phase 4 68-41-7 401 6234
31
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
32
Cysteamine Approved, Investigational Phase 4 60-23-1 6058
33
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
34
Imipramine Approved Phase 4 50-49-7 3696
35
Norepinephrine Approved Phase 4 51-41-2 439260
36
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
37
Nortriptyline Approved Phase 4 72-69-5 4543
38
Hydralazine Approved Phase 4 86-54-4 3637
39
Clevidipine Approved, Investigational Phase 4 167221-71-8
40
Clonidine Approved Phase 4 4205-90-7 2803
41
Ticagrelor Approved Phase 4 274693-27-5 9871419
42
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
43
Liraglutide Approved Phase 4 204656-20-2 44147092
44
Pasireotide Approved Phase 4 396091-73-9 9941444
45
Parecoxib Approved Phase 4 198470-84-7
46
Dobutamine Approved Phase 4 34368-04-2 36811
47
Codeine Approved, Illicit Phase 4 76-57-3 5284371
48
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
49
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
50
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8

Interventional clinical trials:

(show top 50) (show all 2887)
# Name Status NCT ID Phase Drugs
1 Prospective Open Label Evaluation of Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy: A Pilot Study Unknown status NCT02726919 Phase 4 Clobazam
2 A Randomised Controlled Trial of the Ketogenic Diet in the Treatment of Epilepsy in Children Under the Age of Two Years Unknown status NCT02205931 Phase 4 Antiepileptic drug therapy
3 Study to Improve the Treatment of Epilepsy (SITE). A Randomized Study Comparing Adjustment of Treatment to Reduce Side Effects of Antiepileptic Drugs With Continuing Treatment Unchanged Unknown status NCT00133081 Phase 4 All registered antiepileptic drugs
4 Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody Unknown status NCT02695797 Phase 4 Prednisolone
5 Efficacy of Levetiracetam in Control of Neonatal Seizures Unknown status NCT03107507 Phase 4 Levetiracetam;Phenobarbital
6 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
7 Comparing Ketogenic Diet With the Most Appropriate Antiepileptic Drug- a Randomized Study of Children With Mental Retardation and Drug Resistant Epilepsy Unknown status NCT00552526 Phase 4 Antiepileptic drug (AED)
8 A Randomized Controlled Trial of Generic Substitution of Antiepileptic Drugs Unknown status NCT02429596 Phase 4 Experimental
9 Double Blind, Randomised, Cross-over Study Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects Unknown status NCT01370486 Phase 4 melatonin;placebo
10 Hormone Profiles in Adults Treated With Valproate vs. Lamotrigine Monotherapy for Newly Diagnosed Epilepsy: A Prospective Randomised Study Unknown status NCT00137709 Phase 4 Sodium valproate;Lamotrigine
11 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) - a Placebo Controlled Double-blind Cross-over-study Unknown status NCT00393614 Phase 4 levetiracetam
12 Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy: Efficacy, Tolerability, Dosing Equivalence, and Retention Rate Unknown status NCT01932502 Phase 4 clobazam (Onfi);Initial conversion and titration;Conversion schedule - Week 1;Conversion schedule - Week 2;Conversion schedule - Week 3
13 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
14 Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy Unknown status NCT02900755 Phase 4 Perampanel
15 Melatonin Use in the Intensive Care Elderly Population Unknown status NCT03013790 Phase 4 Melatonin
16 Combining Propofol With Therapeutic Hypothermia for Improving Survival and Neurological Prognoses in Patients Resuscitated From Cardiac Arrest Unknown status NCT02367755 Phase 4 Propofol;Lorazepam
17 Turgut Ozal Medical Center Department of Anesthesiology and Reanimation Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
18 Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. A Multi-center Comparative Randomized Double-blind and Placebo-controlled Clinical Trial Unknown status NCT01478035 Phase 4 Phenytoin;placebo
19 Inonu University, Turgut Ozal Medical Center, Department of Anesthesiology and Reanimation Malatya Unknown status NCT02271555 Phase 4 Sevoflurane;Remifentanil;Saline
20 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
21 Conversion From Multiple-Daily Dose Enteric-Coated Depakote to Once-Daily Depakote ER in Elderly Outpatients With Epilepsy or Behavioral Disturbances: Unknown status NCT00312676 Phase 4
22 Relationship Between Topiramate Use and Ocular Angle Status: A Prospective Pilot Study Unknown status NCT00153699 Phase 4 Topiramate
23 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients With Headache and Dizziness or Epilepsy and Clinical Indication for an Angiography by Magnetic Imaging Unknown status NCT00132223 Phase 4 Contrast agent
24 Buccal Midazolam Versus Nasal or Oral Midazolam Sedation for Minor Invasive Procedures in Children: A Prospective Randomized Control Study Unknown status NCT02408302 Phase 4 Midazolam
25 Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine. Unknown status NCT01319825 Phase 4 milnacipran
26 Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates Unknown status NCT02645279 Phase 4 IV midazolam
27 A Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Intra-articular Catheter (IAC) Following Primary Total Knee Arthroplasty Unknown status NCT02497911 Phase 4 Ropivicaine;Bupivicaine
28 The Effect of Central Insulin on Insulin Sensitivity and Energy Metabolism Unknown status NCT01479075 Phase 4 intransal insulin;Placebo
29 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
30 A Double-Blinded Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Local Infiltration of Analgesia (LIA) Following Primary Total Knee Arthroplasty Unknown status NCT02603900 Phase 4 ropivacaine;bupivacaine
31 Effect of Bispectral Index (BIS) Monitoring on Faster Recovery Time and Analgesic Consumption in Abdominal Surgery Patients Unknown status NCT01470898 Phase 4
32 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
33 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Unknown status NCT02920593 Phase 4 Vitamin D3
34 Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome Unknown status NCT02851303 Phase 4 Morphine;Methadone
35 Pharmacokinetic/Pharmacodynamic Model of Propofol in Children Unknown status NCT02544854 Phase 4 Propofol
36 Evaluation Whether Higher Retention Rate is in Those of Combined Methadone With N-Acetyl-Cysteine Compared to Those With Methadone Alone During a Six-month Study Unknown status NCT01047956 Phase 4 Methadone; NAC;Methadone
37 DDAVP vs Exercise in Patients With Mild Hemophilia A - Which is Better and do They Work Synergistically in Improving Hemostasis? Unknown status NCT03136003 Phase 4 DDAVP
38 Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
39 Effect of Botox Treatment for Neurogenic Detrusor Overactivity on the Prevention of Autonomic Dysreflexia Following Spinal Cord Injury Unknown status NCT02298660 Phase 4 BOTOX
40 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
41 Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau. Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
42 A Randomized, Open Label, Comparative, Multi-center Clinical Trial to Determine the Efficacy and Safety of Topiramate Comparing With Carbamazepine in Benign Rolandic Epilepsy. Completed NCT00216567 Phase 4 topamax
43 A 24-Week Prospective, Open-Label, Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Adult Patients With Partial Seizures Completed NCT00275925 Phase 4 Oxcarbazepine
44 A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures. Completed NCT00537940 Phase 4 Pregabalin;Gabapentin
45 A 24-week Prospective Open-label Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures Completed NCT00275912 Phase 4 Oxcarbazepine
46 OAETREAT Extra Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy: a Completed NCT03852303 Phase 4 ivermectin
47 A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy Completed NCT01140867 Phase 4 zonisamide
48 IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures Completed NCT00510783 Phase 4 Keppra;Fosphenytoin;Dilantin
49 A Randomized, Open-label, Parallel Group, Multi-center, Comparative, Phase IV Trial of Levetiracetam (LEV) Versus Topiramate (TPM) as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures Completed NCT01229735 Phase 4 Levetiracetam;Topiramate
50 Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy Completed NCT00004637 Phase 4 Vitamin E

Search NIH Clinical Center for Seizure Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Anti-epileptic Agent [EPC]
Divalproex Sodium
Ethosuximide
Ethotoin
felbamate
fosphenytoin
Fosphenytoin sodium
gabapentin
gabapentin enacarbil
lacosamide
lamotrigine
Levetiracetam
Mephenytoin
methsuximide
oxcarbazepine
Phenytoin
Phenytoin sodium
PHENYTOIN SODIUM,EXTENDED
PHENYTOIN SODIUM,PROMPT
Primidone
Sodium Valproate
tiagabine
Tiagabine hydrochloride
topiramate
Trimethadione
Valproic Acid
Vigabatrin
zonisamide

Genetic Tests for Seizure Disorder

Genetic tests related to Seizure Disorder:

# Genetic test Affiliating Genes
1 Seizures 29
2 Seizure 29

Anatomical Context for Seizure Disorder

MalaCards organs/tissues related to Seizure Disorder:

40
Brain, Temporal Lobe, Cortex, Testes, Amygdala, Heart, Bone

Publications for Seizure Disorder

Articles related to Seizure Disorder:

(show top 50) (show all 31702)
# Title Authors PMID Year
1
ECS Dynamism and Its Influence on Neuronal Excitability and Seizures. 61 42
30879174 2019
2
Testicular mixed germ cell tumor presenting with seizure as the initial symptom: a case report and literature review. 42
30912892 2019
3
Closing the Disclosure Gap: Medical Errors in Pediatrics. 42
30867262 2019
4
Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. 61
31862249 2020
5
Astrocytic modulation of potassium under seizures. 61
31823867 2020
6
Long-term mortality of patients admitted to an intensive care unit with seizures: a population-based study. 61
32022911 2020
7
Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures. 61
31878820 2020
8
Seizures in newborn infants without hypoxic ischemic encephalopathy - antenatal and labor-related risk factors: a case-control study. 61
30373414 2020
9
Reversible splenial lesion in a patient with new-onset refractory status epilepticus (NORSE). 61
31909228 2020
10
Tocilizumab in pediatric refractory status epilepticus and acute epilepsy: Experience in two patients. 61
31935626 2020
11
Current Evidence and Future Directions of Tranexamic Acid Use, Efficacy, and Dosing for Major Surgical Procedures. 61
31455576 2020
12
Antiepileptic effects of electrical stimulation of the piriform cortex. 61
31778664 2020
13
Pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency in zebrafish results in fatal seizures and metabolic aberrations. 61
31759955 2020
14
Treatment of pediatric high-grade central nervous system tumors with high-dose methotrexate in combination with multiagent chemotherapy: A single-institution experience. 61
31850678 2020
15
Phenytoin Pharmacokinetics and Cardiopulmonary Bypass: A Case of Seizures in the Postoperative Period. 61
31852595 2020
16
Increased Seizure Frequency Temporally Related to Vaping: Where There's Vapor, There's Seizures? 61
31917097 2020
17
Loss of presenilin 2 age-dependently alters susceptibility to acute seizures and kindling acquisition. 61
31862541 2020
18
Preclinical testing of the ketogenic diet in fragile X mice. 61
31958482 2020
19
Comparison of fiber tract low frequency stimulation to focal and ANT stimulation in an acute rat model of focal cortical seizures. 61
31902689 2020
20
Does vaping cause seizures? The need for comprehensive drug testing. 61
31116046 2020
21
Monitoring for Poststroke Seizures. 61
32014163 2020
22
Early seizures after ischemic stroke: focus on thrombolysis. 61
30915936 2020
23
Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant. 61
32026356 2020
24
SCN1A Variants in vaccine-related febrile seizures: A prospective study. 61
31755124 2020
25
SCN8A heterozygous variants are associated with anoxic-epileptic seizures. 61
32040247 2020
26
Predictors of clinically urgent intracranial pathology at neuroimaging in children with complex febrile seizures: a retrospective cross-sectional study. 61
31310688 2020
27
Refractory seizures: Prediction of outcome of surgical intervention based on results from PET-CT, PET-MRI and electroencephaolography. 61
31637946 2020
28
The potential effects of anticonvulsant drugs on neuropeptides and neurotrophins in pentylenetetrazol kindled seizures in the rat. 61
31518546 2020
29
Atmospheric Solids Analysis Probe Coupled to a Portable Mass Spectrometer for Rapid Identification of Bulk Drug Seizures. 61
32031401 2020
30
Nebivolol attenuates the anticonvulsant action of carbamazepine and phenobarbital against the maximal electroshock-induced seizures in mice. 61
32016836 2020
31
Variation in Prehospital Protocols for Pediatric Seizure Within the United States. 61
32011553 2020
32
The piriform cortex in epilepsy: What we learn from the kindling model. 61
31794746 2020
33
Encephalopathy related to status epilepticus during slow sleep (ESES) as atypical evolution of Panayiotopoulos syndrome: an EEG and neuropsychological study. 61
32020894 2020
34
De novo SCAMP5 mutation causes a neurodevelopmental disorder with autistic features and seizures. 61
31439720 2020
35
Expanding the phenotype of the CDKL5 deficiency disorder: Are seizures mandatory? 61
32034940 2020
36
Expanding the Phenotype: Neurodevelopmental Disorder, Mitochondrial, With Abnormal Movements and Lactic Acidosis, With or Without Seizures (NEMMLAS) Due to WARS2 Biallelic Variants, Encoding Mitochondrial Tryptophanyl-tRNA Synthase. 61
31684799 2020
37
Treatment initiation decisions in newly diagnosed epilepsy-A longitudinal cohort study. 61
32020603 2020
38
Activation of small conductance calcium-activated potassium channels suppresses seizure susceptibility in the genetically epilepsy-prone rats. 61
31783064 2020
39
Epilepsy and Physical Activity in US Adults. 61
32016438 2020
40
The Beneficence of Cuddle Therapy in Hyperekplexia: A Case Report. 61
31567315 2020
41
Cardiorespiratory depression from brainstem seizure activity in freely moving rats. 61
31669732 2020
42
Developmental Regression and Epilepsy of Infancy with Migrating Focal Seizures Caused by TBCD Mutation: A Case Report and Review of the Literature. 61
31569255 2020
43
Influence of a Comorbid Diagnosis of Seizure on 30-Day Readmission Rates Following Hospitalization for an Index Stroke. 61
31784379 2020
44
Mindfulness-based therapy for psychogenic nonepileptic seizures. 61
31680023 2020
45
Older Patients May Have More Frequent Seizures among Children Diagnosed as Benign Convulsions with Mild Gastroenteritis. 61
32016943 2020
46
Risk factors for preoperative seizures in pediatric patients with intracranial aneurysms. 61
31809890 2020
47
First add-on perampanel for focal-onset seizures: An open-label, prospective study. 61
31745975 2020
48
Risk of febrile seizures among children conceived following fertility treatment: A cohort study. 61
32027053 2020
49
Job consultation in patients with psychogenic nonepileptic seizures: Systematic review and survey of physicians' opinion. 61
31899167 2020
50
Disability benefits in patients with psychogenic nonepileptic seizures: a survey of physicians' opinions. 61
31937514 2020

Variations for Seizure Disorder

ClinVar genetic disease variations for Seizure Disorder:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 DIAPH1 NM_005219.5(DIAPH1):c.2332C>T (p.Gln778Ter)SNV Pathogenic/Likely pathogenic 183344 rs730882242 5:140953085-140953085 5:141573518-141573518
2 MTR NM_000254.2(MTR):c.3518C>T (p.Pro1173Leu)SNV Pathogenic/Likely pathogenic 14278 rs121913578 1:237058770-237058770 1:236895470-236895470
3 SCN1A NM_006920.6(SCN1A):c.1625G>A (p.Arg542Gln)SNV Conflicting interpretations of pathogenicity 68588 rs121918817 2:166901590-166901590 2:166045080-166045080

Expression for Seizure Disorder

Search GEO for disease gene expression data for Seizure Disorder.

Pathways for Seizure Disorder

Pathways related to Seizure Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.99 SCN2A SCN1A MECP2 KCNQ2
2
Show member pathways
11.23 SCN2A SCN1A KCNQ2
3 10.28 SCN2A SCN1A KCNQ2

GO Terms for Seizure Disorder

Cellular components related to Seizure Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glutamatergic synapse GO:0098978 9.71 SCN2A NLGN1 CDKL5 AP3D1
2 postsynapse GO:0098794 9.54 NLGN1 MECP2 AP3D1
3 axon initial segment GO:0043194 9.32 SCN1A KCNQ2
4 voltage-gated sodium channel complex GO:0001518 9.26 SCN2A SCN1A
5 AP-3 adaptor complex GO:0030123 9.16 VPS11 AP3D1
6 sodium channel complex GO:0034706 8.96 SCN2A SCN1A
7 node of Ranvier GO:0033268 8.8 SCN2A SCN1A KCNQ2

Biological processes related to Seizure Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection development GO:0031175 9.5 TBC1D24 NLGN1 MECP2
2 positive regulation of dendritic spine development GO:0060999 9.26 NLGN1 CDKL5
3 membrane depolarization during action potential GO:0086010 9.16 SCN2A SCN1A
4 neuromuscular process controlling posture GO:0050884 8.96 SCN1A MECP2
5 regulation of respiratory gaseous exchange by neurological system process GO:0002087 8.62 NLGN1 MECP2

Molecular functions related to Seizure Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated sodium channel activity GO:0005248 8.96 SCN2A SCN1A
2 voltage-gated ion channel activity GO:0005244 8.8 SCN2A SCN1A KCNQ2

Sources for Seizure Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....